WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsTriSalus Life Sciences Inc. (TLSI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 45580% more annual revenue ($20.63B vs $45.15M). GEHC leads profitability with a 10.1% profit margin vs -86.9%. GEHC earns a higher WallStSmart Score of 60/100 (C+).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

TLSI

Avoid

25

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Intrinsic value data unavailable for TLSI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

TLSI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
59.8%10/10

Revenue surging 59.8% year-over-year

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

TLSI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$238.48M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-5.0%2/10

ROE of -5.0% — below average capital efficiency

Free Cash FlowQuality
$-2.52M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : TLSI

The strongest argument for TLSI centers on Revenue Growth. Revenue growth of 59.8% demonstrates continued momentum.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : TLSI

The primary concerns for TLSI are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

GEHC profiles as a value stock while TLSI is a hypergrowth play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

TLSI is growing revenue faster at 59.8% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 25/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

TriSalus Life Sciences Inc.

HEALTHCARE · MEDICAL DEVICES · USA

TriSalus Life Sciences Inc. (TLSI) is a cutting-edge biopharmaceutical firm committed to transforming cancer therapies through its proprietary localized drug delivery technologies. By enhancing the efficacy of immuno-oncology agents and overcoming significant distribution barriers within the tumor microenvironment, TriSalus aims to significantly improve patient outcomes in oncology. The company is advancing a robust pipeline of clinical programs that reflect its innovative approach and dedication to addressing the unmet needs of patients with challenging cancers. With a focus on expanding access to effective therapies, TriSalus is well-positioned to make a meaningful impact in the field of cancer treatment.

Want to dig deeper into these stocks?